Document Detail


Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension.
MedLine Citation:
PMID:  9926277     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Increased sympathetic activity seems to play an important role in the pathogenesis and development of complications of atherosclerotic origin in patients with essential hypertension (EH). The aim of this study was to evaluate the effect of a new antihypertensive agent, moxonidine (M), on microalbuminuria (urine albumin excretion, UAE), plasma thrombomodulin (TM), and tissue plasminogen activator inhibitor (PAI-1) in patients with mild to moderate EH associated with increased UAE. Fifty-eight patients (32 M, 26 F) with EH and microalbuminuria, with a mean age of 56.6 +/- 8.2 years and a body mass index (BMI) of 23.8 +/- 3.1 kg/m2 who responded to M therapy (0.3-0.4 mg/daily) were studied before and after their blood pressure control. The 24-hour urine albumin excretion (RIA method), as well as TM and PAI-1 plasma levels (ELISA method), were determined before and 6 months after the initiation of treatment under moxonidine therapy. At the end of the 6-month period, all patients remained normotensive. The 24-hour urine albumin excretion had decreased to 24.5 +/- 6.4 vs. 32.3 +/- 7.2 ug/min before therapy (P < 0.001). The plasma TM levels had decreased to 44.0 +/- 7 vs. 51.0 +/- 9 ng/mL before therapy (P < 0.01), and PAI-1 levels had also decreased to 11.5 +/- 4.5 vs. 15.8 +/- 8 IU/mL before therapy (P < 0.05). The results of our study suggest that in hypertensive patients with microalbuminuria, moxonidine, an imidazoline I1-receptor agonist, a new centrally acting antihypertensive agent, significantly reduces urine albumin excretion as well as thrombomodulin and PAI-1 levels. These preliminary findings demonstrate a favorable effect on renal function and endothelial homeostatic mechanisms (maintenance of haemostatic balance).
Authors:
P G Krespi; T K Makris; A N Hatzizacharias; P Triposkiadis; C Tsoukala; D Kyriaki; V Votteas; M Kyriakidis
Related Documents :
1168957 - New approach to the study of hormone-protein interaction using the microcalorimetric me...
1718737 - A novel method for specific visualisation of serum albumin in polyacrylamide gels by io...
1728907 - Serum albumin level on admission as a predictor of death, length of stay, and readmission.
476867 - The effect of fluid volume loading on exclusion of interstitial albumin and lymph flow ...
3229857 - Progesterone assay by inhibition of reverse passive haemagglutination.
103717 - Sex steroids and sex-hormone binding globulin in males with chronic alcoholism.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  12     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1999-03-30     Completed Date:  1999-03-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  463-7     Citation Subset:  IM    
Affiliation:
Athens University, Medical School, Department of Cardiology, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Albuminuria / drug therapy*
Antihypertensive Agents / therapeutic use*
Female
Humans
Imidazoles / therapeutic use*
Male
Middle Aged
Plasminogen Activator Inhibitor 1 / metabolism*
Thrombomodulin / metabolism*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Imidazoles; 0/Plasminogen Activator Inhibitor 1; 0/Thrombomodulin; 75438-57-2/moxonidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Short-term estrogen reduces myocardial infarct size in oophorectomized female rabbits in a dose-depe...
Next Document:  Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on...